Twitter | Search | |
sylvie bonvalot
MD, PHD, HDR Head Sarcoma Surgery Institut Curie Paris
9
Tweets
66
Following
134
Followers
Tweets
sylvie bonvalot Nov 14
Replying to @jeffreyfarma
Further development is ongoing. In Us at MDA
Reply Retweet Like
sylvie bonvalot retweeted
Angela Hong Nov 14
This is an important slide: it is possible to do high quality randomized in with international collaboration
Reply Retweet Like
sylvie bonvalot retweeted
David Gyorki Nov 13
Fantastic to see so much enthusiasm to gain a better understanding of this complex group of diseases through international collaboration.
Reply Retweet Like
sylvie bonvalot Nov 14
Thanks!
Reply Retweet Like
sylvie bonvalot retweeted
Jeffrey Farma Nov 14
Interesting use of hafnium oxide and in with improved pathologic response
Reply Retweet Like
sylvie bonvalot retweeted
Alessandro Gronchi Oct 10
Replying to @12crc @FioreDoc and 3 others
Present evidence points to the opposite direction... see for example Delaying re-excision looks safe. Time for a trial!
Reply Retweet Like
sylvie bonvalot retweeted
SPAEN Oct 11
GIST? Sarcoma? Desmoid tumour? Seek treatment in specialised centers and by experienced experts and expert teams - it is crucial for your prognosis!
Reply Retweet Like
sylvie bonvalot Jul 16
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Reply Retweet Like
sylvie bonvalot Jul 16
Addition of Preoperative NBTXR3 to Radiotherapy in Locally Advanced Soft-Tissue Sarcoma - The ASCO Post
Reply Retweet Like